Replies to post #2916 on Bioelectronics Corp (BIEL)

[art35]

July 23, 2009 - 9:30 AM EDT

close Email this News Article
Your Name
Your Email
Friend's Name
Friend's Email
Receive Copy: yes

BIEL 0.054 0.002

Today 5d 1m 3m 1y 5y 10y



Skymark Research Initiates Complimentary Research Coverage On BioElectronics Corporation
Skymark Research Initiates Complimentary Research Coverage On BioElectronics Corporation
CALGARY, Alberta, July 23, 2009 (GLOBE NEWSWIRE) -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on BioElectronics Corporation (Pink Sheets:BIEL). Skymark Research is currently offering a complimentary trial subscription. To view our research go to: www.skymarkresearch.com

About SMR:

Skymark Research is a leading provider of independent investment research in North America. Our services include research analysis on the small- and micro-cap markets, real-time news and financial data, market commentary and the SMR newsletter. Skymark Research's staff of small-cap investment professionals is dedicated to providing the small market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, go to www.skymarkresearch.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.skymarkresearch.com/signup.php

About BioElectronics Corp.(Pink Sheets:BIEL):

BioElectronics Corporation (Pink Sheets:BIEL) is the maker of ActiPatch(r) Therapy, RecoveryRx(tm) Devices, HealFast(tm) Therapy (www.healfasttherapy.com) and the Allay(tm) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.

SMR Disclosure:

Skymarkresearch.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Skymark Research has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, www.skymarkresearch.com, for complete risks and disclosures.

CONTACT: Skymark Research
Dylan Boyle
202-657-6249
[e-mail]



Source: GlobeNewswire (July 23, 2009 - 9:30 AM EDT)

ALSO---THAT 6 MILLION SHARE TRADE CO8ULD BE A CATCH-UP PRINT FROM AN EARLIER TRADE--